Dr. Kiprilov is a California Medical Board licensed physician scientist who has extensive research and clinical training in oncology, pathology, biomarkers, medical diagnostics and personalized medicine. He completed his undergraduate degree in Biochemical Sciences at Harvard University, his master’s degree in Molecular Pharmacology and his medical degree at a combined medical scientist training program at the Albert Einstein College of Medicine in New York City. His published graduate doctoral research work focused on human embryonic stem cell differentiation. During his residency training at the University of California, Davis he performed clinical research in transfusion medicine and apheresis on peripheral blood stem cell stimulation and collection for stem cell transplantation.
During his industry experience he helped build the Oncology team at the Medical & Scientific Affairs department at Amgen and led the Kyprolis integration of Onyx Pharmaceuticals. He also contributed significantly to building relationships with key opinion leaders in the US West Coast region as part of the Immuno-Oncology Regional Medical Liaison team at Amgen. As Medical Director at Halozyme he served in increased roles of responsibility heading the Medical Research Program for ISTs and providing medical and clinical subject matter expertise on the Alliance board to pharmaceutical partners including Roche, Pfizer, Eli Lilly, Janssen, Abbvie and Shire. In these roles he worked cross-functionally with internal stakeholders in the Medical Affairs, Clinical Development, Early Development, Translational Sciences & Biomarkers, Clinical Operations, Business Development, and Commercial groups.